AKTS earnings date and last-quarter result: next report 2026-08-10, last quarter miss, P/E -40.67. Updated 2026-07-23.
Aktis Oncology (AKTS) Research Hub
Aktis Oncology (AKTS) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 15.73 USD (0.00%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -40.67, market cap 1.31B. This hub links to the full technical, earnings and options research available for AKTS.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 15.73 USD (0.00%) |
| 52-week range | 14.84 USD – 34.19 USD |
| Trend regime | Range |
| 14-day RSI | 33.9 (Bearish) |
| Trailing P/E | -40.67 |
| Market cap | 1.31B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for AKTS
Covered Call on AKTS: how it works, illustrative setup around the real 15.73 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on AKTS: how it works, illustrative setup around the real 15.73 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on AKTS: how it works, illustrative setup around the real 15.73 USD price, max profit/loss, breakeven and when to use it. Educational.
AKTS technical analysis: range, last 15.73 USD, RSI 33.9, 52w range 14.84 USD–34.19 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is AKTS in?
Aktis Oncology (AKTS) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is AKTS in an uptrend or downtrend?
As of 2026-10-26, AKTS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is AKTS's trailing P/E ratio?
AKTS's trailing P/E is -40.67, with a market cap of 1.31B. See the earnings research page for full valuation detail.
When does AKTS next report earnings?
AKTS is next scheduled to report earnings on 2026-08-10.